PE-22-28: Risks & Legal Status

Critical Safety Information#

PE-22-28 is not approved for any therapeutic use. It has been characterized in a single publication from one research group. No human safety, efficacy, or pharmacokinetic data exist. The consequences of sustained TREK-1 channel blockade in humans are unknown.

Risk Categories#

No Human Safety Data#

The entire evidence base for PE-22-28 consists of in vitro electrophysiology, cell culture experiments, and acute/sub-chronic mouse behavioral studies from a single laboratory. No dose-ranging studies, formal toxicology assessments, or human pharmacokinetic studies have been conducted.

Single-Source Evidence#

All published PE-22-28 data comes from the Mazella/Borsotto laboratory at Universite Cote d'Azur (formerly Universite de Nice). While the pharmacological data appears rigorous, scientific findings require independent replication before they can be considered reliable.

TREK-1 Blockade Risks#

TREK-1 channels serve multiple physiological functions:

• Neuroprotection: TREK-1 is upregulated during ischemia and protects neurons from excitotoxic death. Chronic blockade could increase stroke vulnerability.
• Pain modulation: TREK-1 contributes to pain processing. Blockade may alter pain sensitivity.
• Cardiac function: TREK-1 is expressed in cardiac tissue and contributes to action potential regulation.

Legal and Regulatory Status#

Risk Assessment Context#

PE-22-28 belongs to the Neuropeptide category of research peptides. Risk assessment for PE-22-28 should consider both the compound-specific risks identified in clinical research and the broader regulatory environment. Researchers and healthcare providers should evaluate these risks in the context of the specific patient population and therapeutic indication.

Risk Categories#

The following risk categories have been identified for PE-22-28 based on available evidence and regulatory assessments:

No Human Safety Data#

PE-22-28 has never been tested in humans. All data comes from mouse studies by a single research group.

Single-Source Evidence#

All published data originates from one laboratory at Universite Cote d'Azur. No independent replication of efficacy or safety findings exists.

Unknown Chronic Effects of TREK-1 Blockade#

TREK-1 channels serve neuroprotective functions during ischemia. Chronic blockade could increase vulnerability to stroke or ischemic brain injury.

Regulatory Status by Jurisdiction#

The regulatory and legal status of PE-22-28 varies by country and jurisdiction. Researchers should verify current regulations before acquiring or using this compound.

Regulatory classifications can change. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction.

Important Warnings#

The following warnings apply to PE-22-28:

• NOT FOR HUMAN USE: PE-22-28 has not undergone any human clinical trials and has no established safety profile in humans.
• SINGLE-SOURCE DATA: All research comes from one laboratory with no independent replication. Findings should be considered preliminary.
• ISCHEMIC RISK: TREK-1 channels provide neuroprotection during ischemia. Blocking these channels may increase vulnerability to ischemic brain injury.

These warnings are based on available preclinical and clinical data. The absence of a warning does not indicate safety. Consult qualified professionals before making any decisions regarding peptide research.

Related Reading#

• PE-22-28 overview and research guide
• PE-22-28 side effects profile
• PE-22-28 research evidence